Low molecular weight heparin (LMWH) for primary thrombo-prophylaxis in patients with solid malignancies – systematic review and meta-analysis

References

• Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 2007;15:2339–46.
   Web of Science ®Google Scholar
• Khorana AA, Dalal M, Lin J, Connolly GC. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer 2013;119:648–55.
   PubMed Web of Science ®Google Scholar
• Levitan N, Dowlati A, Remick SC, Tahsildar HI, Sivinski LD, Beyth R, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999;78:285–91.
   PubMed Web of Science ®Google Scholar
• Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006; 166:458–66.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013;31:2189–204.
   PubMed Web of Science ®Google Scholar
• Heit JA, Silverstein MD, Mohr DN, Petterson TM, Lohse CM, O’Fallon WM, et al. Risk factors for deep vein thrombosis and pulmonary embolism: A population-based case-control study. Arch Intern Med 2000;160:809–15.
   PubMed Web of Science ®Google Scholar
• Haddad TC, Greeno EW. Chemotherapy-induced thrombosis. Thromb Res 2006;118:555–68.
   PubMed Web of Science ®Google Scholar
• Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis. JAMA 2008; 300:2277–85.
   PubMed Web of Science ®Google Scholar
• Palumbo JS, Kombrinck KW, Drew AF, Grimes TS, Kiser JH, Degen JL, et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 2000;96:3302–9.
   PubMed Web of Science ®Google Scholar
• Palumbo JS, Potter JM, Kaplan LS, Talmage K, Jackson DG, Degen JL. Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen deficient mice. Cancer Res 2002; 62:6966–72.
   PubMed Web of Science ®Google Scholar
• Sampson MT, Kakkar AK. Coagulation proteases and human cancer. Biochem Soc Trans 2002;30:201–7.
   PubMed Web of Science ®Google Scholar
• Rickles FR, Patierno S, Fernandez PM. Tissue factor, thrombin, and cancer. Chest 2003;124:58S–68S.
   PubMed Web of Science ®Google Scholar
• Khorana AA, Streiff MB, Farge D, Mandala M, Debourdeau P, Cajfinger F, et al. Venous thromboembolism prophylaxis and treatment in cancer: A consensus statement of major guidelines panels and call to action. J Clin Oncol 2009;27:4919–22.
   PubMed Web of Science ®Google Scholar
• Debourdeau P, Farge D, Beckers M, Baglin C, Bauersachs RM, Brenner B, et al. International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer. J Thromb Haemost 2013;11:71–8.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions Version 5.0. The Cochrane Collaboration. [cited 2013 Aug 10]. Available from: www.cochrane-handbook.org. 2008.
   Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177–88.
   PubMed Web of Science ®Google Scholar
• Altinbas M, Coskun HS, Er O, Ozkan M, Eser B, Unal A, et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2004;2:1266–71.
   PubMed Web of Science ®Google Scholar
• Kakkar AK, Levine MN, Kadziola Z, Lemoine NR, Low V, Patel HK, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: The fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004;22:1944–8.
   PubMed Web of Science ®Google Scholar
• Klerk CPW, Smorenburg SM, Otten HM, Lensing AW, Prins MH, Piovella F, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005;23:2130–5.
   PubMed Web of Science ®Google Scholar
• Sideras K, Schaefer PL, Okuno SH, Sloan JA, Kutteh L, Fitch TR, et al. Low-molecular-weight heparin in patients with advanced cancer: A phase 3 clinical trial. Mayo Clin Proc 2006;81:758–67.
   PubMed Web of Science ®Google Scholar
• Agnelli G, Gussoni G, Bianchini C, Verso M, Mandalà M, Cavanna L, et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: A randomised, placebo-controlled, double blind study. Lancet Oncol 2009;10:943–9.
   PubMed Web of Science ®Google Scholar
• Riess H, Pelzer U, Deutschinoff G, Opitz M, Stauch P, Reitzig S, et al. A prospective, randomized trial of chemotherapy with or without the low molecular weight heparin (LMWH) enoxaparin in patients (pts) with advanced pancreatic cancer (APC): Results of the CONKO 004 trial. J Clin Oncol 2009;27:18S.
   Web of Science ®Google Scholar
• van Doormaal FF, Di Nisio M, Otten HM, Richel DJ, Prins M, Buller HR. Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer. J Clin Oncol 2011;29:2071–6.
   PubMed Web of Science ®Google Scholar
• Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 2012;366:601–9.
   PubMed Web of Science ®Google Scholar
• Maraveyas A, Waters J, Roy R, Fyfe D, Propper D, Lofts F, et al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Eur J Cancer 2012; 48:1283–92.
   PubMed Web of Science ®Google Scholar
• Haas SK, Freund M, Heigener D, Heilmann L, Kemkes-Matthes B, von Tempelhoff GF, et al. Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer. Clin Appl Thromb Hemost 2012;18:159–65.
   PubMed Web of Science ®Google Scholar
• Verso M, Gussoni G, Agnelli G. Prevention of venous thromboembolism in patients with advanced lung cancer receiving chemotherapy: A combined analysis of the PROTECHT and TOPIC-2 studies. J Thromb Haemost 2010;8:1649–51.
   PubMed Web of Science ®Google Scholar
• Bick RL. Alterations of hemostasis associated with malignancy: Etiology, pathophysiology, diagnosis and management. Semin Thromb Hemost 1978;5:1–26.
   PubMed Web of Science ®Google Scholar
• Johnson MJ, Sproule MW, Paul J. The prevalence and associated variables of deep venous thrombosis in patients with advanced cancer. Clin Oncol (R Coll Radiol) 1999;11:105–10.
   PubMed Web of Science ®Google Scholar
• Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005;293:715–22.
   PubMed Web of Science ®Google Scholar
• Alikhan R, Cohen AT, Combe S, Samama MM, Desjardins L, Eldor A, et al. Prevention of venous thromboembolism in medical patients with enoxaparin: A subgroup analysis of the MEDENOX study. Blood Coagul Fibrinolysis 2003;14:341–6.
   PubMed Web of Science ®Google Scholar
• Noble SI, Shelley MD, Coles B, Williams SM, Wilcock A, Johnson MJ;Association for Palliative Medicine for Great Britain and Ireland. Management of venous thromboembolism in patients with advanced cancer: A systematic review and meta-analysis. Lancet Oncol 2008;9:577–84.
   PubMed Web of Science ®Google Scholar
• Weitz JI, Eikelboom JW, Samama MM, American College of Chest Physicians. New antithrombotic drugs: Antithrombotic therapy and prevention of thrombosis, 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e120–51S.
   Google Scholar